GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Rating) – Equities researchers at SVB Leerink lowered their Q3 2022 EPS estimates for GoodRx in a report issued on Monday, August 1st. SVB Leerink analyst S. Davis now expects that the company will post earnings of $0.02 per share for the quarter, down from their prior estimate of $0.03. SVB Leerink currently has a “Market Perform” rating and a $10.00 price objective on the stock. The consensus estimate for GoodRx’s current full-year earnings is $0.03 per share. SVB Leerink also issued estimates for GoodRx’s FY2022 earnings at $0.07 EPS, FY2023 earnings at $0.26 EPS and FY2024 earnings at $0.44 EPS.
GoodRx (NASDAQ:GDRX – Get Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.01. GoodRx had a negative net margin of 1.86% and a positive return on equity of 2.86%. The company had revenue of $203.30 million for the quarter, compared to analysts’ expectations of $200.61 million. During the same quarter in the previous year, the company earned ($0.01) earnings per share. GoodRx’s quarterly revenue was up 26.7% on a year-over-year basis.
GoodRx Price Performance
Shares of NASDAQ GDRX opened at $6.50 on Wednesday. GoodRx has a 1 year low of $5.61 and a 1 year high of $48.05. The company has a debt-to-equity ratio of 0.83, a current ratio of 16.76 and a quick ratio of 16.76. The company’s 50-day moving average is $6.66 and its 200 day moving average is $14.49. The stock has a market capitalization of $2.58 billion, a P/E ratio of -162.50, a P/E/G ratio of 14.22 and a beta of 0.77.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AdvisorNet Financial Inc increased its holdings in GoodRx by 275.0% during the first quarter. AdvisorNet Financial Inc now owns 1,875 shares of the company’s stock valued at $36,000 after buying an additional 1,375 shares during the last quarter. CWM LLC increased its holdings in GoodRx by 50.2% during the first quarter. CWM LLC now owns 2,224 shares of the company’s stock valued at $43,000 after buying an additional 743 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in GoodRx during the second quarter valued at approximately $59,000. SG Americas Securities LLC purchased a new stake in GoodRx during the second quarter valued at approximately $63,000. Finally, Whittier Trust Co. purchased a new stake in GoodRx during the second quarter valued at approximately $75,000. Institutional investors own 52.60% of the company’s stock.
GoodRx Company Profile
GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.
- Get a free copy of the StockNews.com research report on GoodRx (GDRX)
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn’t Ignore
- Is Nike An Undervalued Opportunity for Investors?
- Proposed Tesla Stock Split Drives EV Market Higher
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.